Featured

Turning up the heat: iSBRT and immunotherapy induce immune reprogramming in cold breast tumors in the clinic

The tumor immune microenvironment (TIME) of ER+HER2- high-risk early breast cancer is generally immune-cold, which limits immune checkpoint blockade (ICB) responses. Since radiotherapy may modulate the immune response, it may increase ICB efficacy....

Enhancement of ferroptosis in escape variant tumor cells by IFN-γ derived from antigen-specific T cells controls tumor with heterogeneity

To enhance immunotherapy efficacy against escape variant clones, Ehara et al. combined MART-1 TCR-T cells with the ferroptosis inducer RSL3. IFNγ secreted by the TCR-T cells enhanced the susceptibilit...

Single-cell transcriptomic analysis reveals tumor-immune determinants of lymph node colonization and progression in thyroid cancer

Nguyen et al. used single-cell RNAseq and multiplex IHC on paired primary thyroid carcinomas and metastatic lymph nodes (LNs) to define immune determinants of nodal colonization. In metastatic LNs, th...

Sustained A2AR expression and loss paradoxically promote CD8+ T cell exhaustion

Using single-cell multiomics and genetic models, Song and Kharel et al. showed that, paradoxically, both sustained A2AR expression under chronic antigen exposure and hypoxia, and complete loss of A2AR...

RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma model

Marx, Teppert, and Marisch et al. showed retinoic acid-inducible gene-I (RIG-I), the cytoplasmic sensor of short dsRNA with uncapped 5’-triphosphate (3p-RNA), was expressed in human HCC samples and in...

See all for this week

Previous Digests

Tregs versus Tconv: a battle over metastasis in PDAC

July 8, 2026

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and difficult-to-treat-tumor type with complex immune dynamics and multiple immune evasion mechanisms at different stages of disease. In work recently published in Science Immunology, Schmiechen et al. unraveled the roles of IFNγ-inducible...

Exhausted, yet effective: Eomes drives Th-mediated antitumor responses

July 1, 2026

While accumulating evidence suggests an important role for CD4+ T cells in antitumor immunity, the specific subpopulations responsible remain to be defined. Agesta, Ferrand, et al. investigated the function of the transcription factor Eomes in CD4+ T cell antitumor...

Neutrophils not so neutral in tumors after all

June 24, 2026

Neutrophils in tumors are known to play both pro- and anti-inflammatory roles, but how they affect responses to immunotherapy is incompletely understood. In work recently published in Immunity, Pei et al. evaluated neutrophils in the context of several cancer...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials